Steven W Martin
Overview
Explore the profile of Steven W Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DHaens G, Reinisch W, Lee S, Tarabar D, Louis E, Klopocka M, et al.
Inflamm Bowel Dis
. 2021 Aug;
28(7):1034-1044.
PMID: 34427633
Background: Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, is a potential novel CD treatment....
2.
Vong C, Martin S, Deng C, Xie R, Ito K, Su C, et al.
Clin Pharmacol Drug Dev
. 2021 Jan;
10(3):229-240.
PMID: 33513294
Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We characterized tofacitinib pharmacokinetics in patients with moderate to severe UC, and the effects...
3.
Schrieber S, Putnam W, Chow E, Cieslak J, Zhuang Y, Martin S, et al.
Drugs R D
. 2020 Sep;
20(4):301-306.
PMID: 32914381
Expedited development programs for biological products to be used in the treatment of serious conditions bring about challenges because of the compressed clinical development timeframes. As expedited development does not...
4.
Rogers K, Martin S, Bhattacharya I, Singh R, Nayak S
Clin Transl Sci
. 2020 Aug;
14(1):249-259.
PMID: 32822115
Inflammatory bowel disease (IBD) is a heterogeneic disease with a variety of treatments targeting different mechanisms. A multistate, mechanistic, mathematical model of IBD was developed in part 1 of this...
5.
Rogers K, Martin S, Bhattacharya I, Singh R, Nayak S
Clin Transl Sci
. 2020 Aug;
14(1):239-248.
PMID: 32822108
A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The...
6.
Mukherjee A, Hazra A, Smith M, Martin S, Mould D, Su C, et al.
Br J Clin Pharmacol
. 2018 Jan;
84(6):1136-1145.
PMID: 29377257
Aims: Tofacitinib is an oral, small molecule JAK inhibitor being investigated for ulcerative colitis (UC). In a phase 2 dose-ranging study, tofacitinib demonstrated efficacy vs. placebo as UC induction therapy....
7.
Kojima K, Nimtz J, Martin S, Guertin S, Cavenagh E
J Radiol Case Rep
. 2018 Jan;
11(7):8-13.
PMID: 29299097
We report a case of nonaccidental trauma (NAT) involving a 23-month-old boy who presented with seizures, acute subarachnoid hemorrhage, and acute subdural hemorrhage. Ophthalmologic examination showed bilateral intraretinal hemorrhages. Further...
8.
Rogers K, Bhattacharya I, Martin S, Nayak S
Clin Transl Sci
. 2017 Oct;
11(1):4-7.
PMID: 28986961
No abstract available.
9.
Hassan-Zahraee M, Banerjee A, Cheng J, Zhang W, Ahmad A, Page K, et al.
J Crohns Colitis
. 2017 Sep;
12(1):77-86.
PMID: 28961803
Objective: To define pharmacodynamic biomarkers in the peripheral blood of patients with Crohn's disease [CD] after treatment with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1] monoclonal antibody. Methods:...
10.
Wu J, Banerjee A, Jin B, Menon S, Martin S, Heatherington A
Stat Methods Med Res
. 2017 Jan;
27(9):2694-2721.
PMID: 28067121
Characterizing clinical dose-response is a critical step in drug development. Uncertainty in the dose-response model when planning a dose-ranging study can often undermine efficiency in both the design and analysis...